

Brain regions related to fear extinction in obsessive-compulsive disorder and its relation to exposure therapy outcome: a morphometric study

M. A. Fullana^{1,2*}, N. Cardoner^{3,4,5}, P. Alonso^{3,4,5}, M. Subirà³, C. López-Solà^{3,4,5}, J. Pujol⁶, C. Segalàs^{3,4}, E. Real^{3,4}, M. Bossa⁷, E. Zacur⁷, I. Martínez-Zalacáin³, A. Bulbena¹, J. M. Menchón^{3,4,5}, S. Olmos⁷ and C. Soriano-Mas^{3,4}

¹Institute of Neuropsychiatry and Addictions (INAD), Hospital del Mar and Department of Psychiatry, Autonomous University of Barcelona, Barcelona, Spain

²King's College London, Institute of Psychiatry, London, UK

³Department of Psychiatry, Bellvitge University Hospital-IDIBELL, Barcelona, Spain

⁴CIBERSAM, Carlos III Health Institute, Spain

⁵Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain

⁶CRC Mar, Hospital del Mar, Barcelona, Spain

⁷Aragon Institute of Engineering Research, University of Zaragoza, Zaragoza, Spain

Background. The size of particular sub-regions within the ventromedial prefrontal cortex (vmPFC) has been associated with fear extinction in humans. Exposure therapy is a form of extinction learning widely used in the treatment of obsessive-compulsive disorder (OCD). Here we investigated the relationship between morphometric measurements of different sub-regions of the vmPFC and exposure therapy outcome in OCD.

Method. A total of 74 OCD patients and 86 healthy controls underwent magnetic resonance imaging (MRI). Cortical thickness and volumetric measurements were obtained for the rostral anterior cingulate cortex (rACC), the medial orbital frontal cortex and the subcallosal cortex. After MRI acquisition, patients were enrolled in an exposure therapy protocol, and we assessed the relationship between MRI-derived measurements and treatment outcome. Baseline between-group differences for such measurements were also assessed.

Results. Compared with healthy controls, OCD patients showed a thinner left rACC ($p=0.008$). Also, left rACC thickness was inversely associated with exposure therapy outcome ($r=-0.32$, $p=0.008$), and this region was significantly thinner in OCD patients who responded to exposure therapy than in those who did not ($p=0.006$). Analyses based on regional volumetry did not yield any significant results.

Conclusions. OCD patients showed cortical thickness reductions in the left rACC, and these alterations were related to exposure therapy outcome. The precise characterization of neuroimaging predictors of treatment response derived from the study of the brain areas involved in fear extinction may optimize exposure therapy planning in OCD and other anxiety disorders.

Received 10 December 2012; Revised 22 April 2013; Accepted 30 April 2013; First published online 18 June 2013

Key words: Brain morphometry, exposure therapy, fear extinction, neuroimaging, obsessive-compulsive disorder.

Introduction

Fear acquisition and extinction have become the focus of much scientific interest in recent years. In the laboratory, fear is acquired when a neutral stimulus (conditioned stimulus) elicits a fear response (conditioned response) after being repeatedly paired with an aversive event (unconditioned stimulus). Fear extinction occurs when the conditioned stimulus is

presented alone and the conditioned response is eventually diminished. Research on how fears are extinguished is especially relevant, since it may inform the treatment of fear/anxiety-related disorders (Graham & Milad, 2011). For example, exposure therapy is the main component of cognitive-behavioural therapy (CBT) for anxiety disorders and relies upon the basic principles of fear extinction (Hofmann, 2007). In exposure therapy, an individual is repeatedly exposed to an event that has previously resulted in aversive consequences until his/her fear diminishes.

Data from the animal literature and recent human neuroimaging studies have delineated the brain areas involved in fear extinction, namely the amygdala, the

* Address for correspondence: M. A. Fullana, Ph.D., Institute of Neuropsychiatry and Addictions (INAD), Hospital del Mar, Passeig Marítim, 25/29, 08003 Barcelona, Spain.
(Email: Miguel.Fullana@kcl.ac.uk)

ventromedial prefrontal cortex (vmPFC) and the hippocampus (Milad & Quirk, 2012). Each of these areas could be related to different extinction mechanisms. While initial extinction learning seems to depend on the amygdala, the consolidation and retention of extinction learning (extinction recall) would seem to depend on the vmPFC (Phelps *et al.* 2004; Kalisch *et al.* 2006; Sotres-Bayon *et al.* 2006; Quirk & Mueller, 2008). In turn, the hippocampus has been associated with the contextual modulation of fear extinction (Bouton, 2004; Milad *et al.* 2007).

Two recent studies have suggested that structural differences in the vmPFC may be associated with differences in fear extinction in humans. Milad *et al.* (2005) were the first to report cortical thickness in one sub-region of the vmPFC, the medial orbital frontal cortex (mOFC), to be associated with extinction recall in a sample of healthy individuals. This finding was recently replicated by an independent research group (Hartley *et al.* 2011). Given that exposure therapy relies on fear extinction mechanisms, it is plausible that the results obtained in fear extinction studies (specifically, those involving extinction recall) translate into the clinical world, i.e. that size variability, in particular vmPFC sub-regions, predicts—at least partially—exposure therapy outcomes. Identifying such predictors could eventually guide treatment planning in anxiety disorders (Rauch *et al.* 2006).

Nevertheless, to date, there have been very few studies on this topic in clinical samples. Bryant *et al.* (2008) used voxel-based morphometry (VBM) to test whether the volume of another vmPFC sub-region, the rostral anterior cingulate cortex (rACC), predicted response to CBT in post-traumatic stress disorder (PTSD) patients. In this study, treatment responders and healthy controls had larger rACC volume than non-responders, and rACC volume was significantly associated with pre- to post-treatment symptom reduction. The study, however, did have a number of limitations, including a small sample ($n=13$), a relatively arbitrary criterion of treatment response (failing to fulfil PTSD criteria after treatment), and a lack of examination of other brain regions known to be involved in fear extinction (e.g. mOFC). Very recently, Hoexter *et al.* (2012), also using VBM techniques, found that the volume of the subgenual ACC (overlapping with the subcallosal cortex; SC) predicted pre- to post-treatment symptom reduction in a sample of treatment-naïve obsessive-compulsive disorder (OCD) patients receiving group CBT as part of a randomized trial. Again, the sample size of this study was relatively small ($n=15$). Furthermore, there was no control group to test for pre-treatment differences in the brain areas studied. This is important, given previous reports of volume reductions in

areas such as the mOFC or the ACC in OCD patients in comparison with healthy controls (Pujol *et al.* 2004; Rotge *et al.* 2009).

Therefore, although previous studies suggest that morphometric variability in different sub-regions of the vmPFC may predict the outcome of exposure therapy (or more generally CBT) in anxiety disorders, there are indeed some conflicting results. Thus, while the volumes of the rACC and the SC were not associated with extinction recall in healthy subjects (Milad *et al.* 2005), they predicted CBT outcome in PTSD and OCD patients (Bryant *et al.* 2008; Hoexter *et al.* 2012). Conversely, to date, morphometry of the mOFC has not been related to CBT outcome in any anxiety disorder.

Methodological differences between studies may explain such divergences, since Milad *et al.* (2005) focused on cortical thickness measurements whereas Bryant *et al.* (2008) and Hoexter *et al.* (2012) assessed regional volumes. Although both cortical thickness and regional volumetry have been widely used as valid measurements of brain morphometry, they refer to partially different aspects of brain structure, since regional volumetry is also influenced by cortical surface area and cortical folding (Hutton *et al.* 2009). Consequently, combining both measurements may be useful to fully characterize brain anatomy (Hutton *et al.* 2009; Labate *et al.* 2012).

In the present study we tested whether morphometric variations in the different sub-regions of the vmPFC were related to exposure therapy outcome in a sample of OCD patients. In addition, baseline morphometric differences in relation to healthy controls were also assessed for these brain areas. Importantly, with the aim of overcoming previous methodological differences between studies and to comprehensively characterize such differences and the correlations between vmPFC sub-regions and exposure therapy outcome, we used regional measurements of both cortical thickness and volume. We focused on OCD in view of the recent interest in 'new' OCD models based on fear extinction deficits (Milad & Rauch, 2012). Furthermore, exposure therapy (using response prevention) is one of the treatments of choice for OCD. From a behavioural perspective, OCD is characterized by the presence of conditioned fear responses (which could be established through Pavlovian aversive conditioning), and exposure (using response prevention, which blocks escape/avoidance) is effective as it provides an opportunity for the extinction of such responses (see Abramowitz, 2006). Exposure is therefore an analogue of extinction training. However, although exposure is a highly effective treatment for OCD, there is significant across-subject variability in treatment response.

Table 1. Sociodemographic and clinical characteristics of study participants

	OCD patients (<i>n</i> =74)	Healthy controls (<i>n</i> =86)	<i>p</i>
Mean age, years (s.d., range)	34.09 (9.21, 19–57)	33.59 (9.76, 18–61)	0.74
Mean age at OCD onset, years (s.d.)	21.5 (7.5)		
Mean duration of education, years (s.d.)	12.4 (3.05)	12.2 (3.1)	0.76
Gender, male, <i>n</i> (%)	38 (51.3)	43 (50)	0.86
Co-morbidity			
Affective disorders, <i>n</i> (%)	13 (17.5)		
Major depressive disorder, <i>n</i>	5		
Dysthymia, <i>n</i>	4		
Depressive disorder not otherwise specified, <i>n</i>	4		
Anxiety disorders, <i>n</i> (%)	9 (12.1)		
Social phobia, <i>n</i>	4		
Panic disorder, <i>n</i>	3		
Generalized anxiety disorder, <i>n</i>	2		
Tic disorders, <i>n</i> (%)	7 (9.45)		
Family history of OCD, <i>n</i> (%)	15 (20.2)		
Mean HAMD baseline (s.d.)	12.9 (4.4)		
Mean YBOCS-obsessions baseline (s.d.)	11.2 (2.6)		
Mean YBOCS-compulsions baseline (s.d.)	11.0 (2.5)		
Mean YBOCS-total baseline (s.d.)	22.2 (5.1)		
Mean YBOCS-obsessions after exposure therapy (s.d.)	7.8 (3.4)		
Mean YBOCS-compulsions after exposure therapy (s.d.)	7.6 (3.3)		
Mean YBOCS-total after exposure therapy (s.d.)	15.4 (6.7)		
Pharmacological treatment, <i>n</i> (%) ^a			
Fluoxetine 60–80 mg/day	37 (50)		
Fluvoxamine 200–300 mg/day	16 (21.6)		
Escitalopram 20–40 mg/day	10 (13.5)		
Clomipramine ^b 225–300 mg/day	11 (14.8)		

OCD, Obsessive-compulsive disorder; s.d. standard deviation; HAMD, Hamilton Depression Rating Scale; YBOCS, Yale–Brown Obsessive-Compulsive Scale.

^a A benzodiazepine tapering protocol was initiated at the beginning of the pharmacological trial.

^b Patients under clomipramine treatment should have reported a previous history of failure with selective serotonin reuptake inhibitors.

On the basis of previous reports (Pujol *et al.* 2004; Venkatasubramanian *et al.* 2012), we predicted that OCD patients would show morphometric alterations in the mOFC and the rACC in comparison with healthy controls. Also based on previous clinical work (Bryant *et al.* 2008; Hoexter *et al.* 2012), we hypothesized that the size of the rACC and SC would be associated with the outcome of exposure therapy for OCD.

Method

Participants

A total of 74 OCD patients and 86 healthy controls were included in the study. Sociodemographic and clinical characteristics of both groups are presented in Table 1. Patients were recruited from the OCD Unit at Bellvitge University Hospital (Barcelona, Spain)

between 2009 and 2011. All patients met Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for OCD (APA, 1994) and had shown OCD symptoms for at least 1 year. Diagnoses were independently assigned by two psychiatrists with extensive clinical experience in OCD, who separately interviewed the patients using the Structured Clinical Interview for DSM-IV Axis I Disorders – Clinician Version (SCID-IV-CV; First *et al.* 1996). Patients were eligible for the study when both clinicians agreed on all diagnostic criteria. Exclusion criteria for the patients were as follows: age under 18 or over 65 years, current or 6-month past history of psychoactive substance abuse/dependence, co-morbid psychotic or bipolar disorders, mental retardation, presence or past history of serious organic or neurological disorder (except tic disorder), and any contraindication to magnetic resonance imaging (MRI)

scanning. Co-morbid depressive and anxiety disorder symptoms were not considered to be exclusion criteria provided that OCD was the main diagnosis and the primary reason for seeking assistance. The presence of lifetime depressive symptoms (including lifetime major depressive disorder, MDD) was also assessed with the SCID-IV-CV.

Healthy controls were recruited from the same socio-demographic environment as patients. Each control underwent the SCID-IV non-patient version (First *et al.* 2002) to exclude any current or past Axis I disorder. The other exclusion criteria were the same as for the OCD group.

Participants in both groups gave written informed consent after receiving a complete description of the study, which was approved by the research and ethics committee of Bellvitge University Hospital. The investigation was carried out in accordance with the Declaration of Helsinki.

Study procedures

OCD patients received an open trial of standard exposure therapy (including response prevention) after partial or non-response to a 12-week pharmacological trial with a selective serotonin reuptake inhibitor or clomipramine following recommended guidelines (Koran *et al.* 2007). After achieving the maximum recommended and tolerated doses of medication, patients initiated exposure therapy. The time lapse between the end of the pharmacological trial and the initiation of exposure therapy ranged between 1 and 2 weeks. During this interval, a structural MRI examination was performed (see below). Importantly, medication was kept stable during exposure therapy (pharmacological profiles are shown in Table 1). Of an initial sample of 83 patients who fulfilled the inclusion criteria, three subjects refusing to initiate exposure therapy and six who dropped out before completing the first five sessions were duly classified as non-completers.

MRI acquisition

Participants in both groups were scanned with a 1.5-T scanner (Signa Excite system; General Electric, USA) equipped with an eight-channel phased-array head coil. A high-resolution T1-weighted anatomical image was obtained for each subject using a three-dimensional fast spoiled gradient inversion-recovery prepared sequence with 130 contiguous slices in the axial plane (repetition time=11.8 ms, echo time=4.2 ms and flip angle=90°, within a field of view of 30 cm, with a 256×256 pixel matrix and a slice thickness of 1.2 mm).

Exposure therapy

Exposure therapy was manualized (Kozak & Foa, 1997) and applied by an experienced therapist who was blind to the study's hypotheses. The study involved 20 individual weekly sessions lasting approximately 45 min. The first two sessions were devoted to psychoeducation, the introduction to the behavioural model of OCD and the development of an exposure hierarchy; sessions 3–18 consisted of gradual exposure to items of the hierarchy, with instructions for strict response prevention from compulsions. Between sessions, homework consisting of exposure to stimuli similar to those addressed in the sessions was assigned (60 min daily). The final two sessions were devoted to relapse prevention.

Assessment and treatment response

The Yale–Brown Obsessive-Compulsive Scale (YBOCS; Goodman *et al.* 1989) was administered by experienced clinicians to the OCD group to assess illness severity both before and after exposure therapy. Co-morbid depressive symptoms were measured by means of the Hamilton Depression Rating Scale (HAMD; Hamilton, 1960).

Treatment response was defined as a 35% or greater decrease in the YBOCS total score according to operational criteria (Pallanti *et al.* 2002), according to which 35 patients (47.2%) were regarded as responders to exposure therapy [mean YBOCS reduction: 49.3 (s.d. =11.0)%] and 39 (52.7%) as non-responders [mean YBOCS reduction: 17.8 (s.d.=10.6)%].

Image processing

After inspection for imaging artefacts, subcortical and cortical parcellation was performed using the publicly available FreeSurfer software (version 5.1; <http://ftp.nmr.mgh.harvard.edu/>). The standard pipeline was used, including a volume- and a surface-based processing stream. Volume-based stream involved the following stages: affine registration to the MNI305 template, initial volumetric labelling, intensity correction for field inhomogeneities, intensity normalization, removal of non-brain tissue and linear and non-linear transformations to a probabilistic brain atlas (Fischl *et al.* 2002, 2004). The surface stream was focused on modelling the boundary between white matter and cortical grey matter (GM; denoted as white surface), in addition to the pial surface. The white surface was parcellated into 74 cortical regions of interest (ROIs) through the assignment of a neuroanatomical label for each surface location (vertex) according to the Destrieux *et al.* (2010) parcellation scheme. Cortical thickness and GM volumes values were then




Fig. 1. Representation of the regions of interest used in this study, which are overlaid on mid-sagittal (a) and ventral (b) sections of a left hemisphere brain template. The medial orbitofrontal cortex is depicted in green, the rostral anterior cingulate cortex in violet, and the subcallosal cortex in yellow.

calculated for the 74 cortical ROIs. Specifically, the distance between the pial and the white surface was calculated for each brain vertex and averaged across all the vertices of each ROI to obtain regional cortical thickness, while regional cortical volumes were calculated by multiplying the number of voxels in each parcelation unit by the voxel volume ($1.17 \times 1.17 \times 1.2$ mm). However, on the basis of our hypotheses, in the present study we only considered three ROIs per hemisphere: (1) mOFC (corresponding to the gyrus rectus plus the medial orbital sulcus); (2) rACC (corresponding to the anterior part of the cingulate gyrus and sulcus); and (3) the SC (corresponding to Brodmann area 25 and the most ventral part of Brodmann area 32). The selected ROIs are displayed in Fig. 1.

Statistical analyses

An analysis of covariance (ANCOVA) was used to compare regional measurements of cortical thickness and volume in the selected ROIs between patients and controls using age, gender, lifetime MDD and total GM volume as covariates. Total GM volume was calculated for each subject by multiplying the number of voxels classified as GM by the voxel volume. In the patient group, partial correlations were calculated between ROI measurements and exposure therapy outcome (percentage of total YBOCS reduction between pre- and post-exposure therapy assessments). In addition, we compared ROI measurements between treatment responders and non-responders also by means of an ANCOVA test. In both analyses related to treatment response, in addition to age, gender, lifetime MDD and total GM volume, we also controlled for pre-exposure therapy HAMD scores and YBOCS reduction after the pharmacological trial. The

Bonferroni correction for multiple comparisons was used, and α was set at $p < 0.0083$ ($0.05/6$ ROIs, three per hemisphere) in each analysis. These analyses were conducted using the Statistical Package for Social Sciences software (SPSS version 20; IBM, USA).

Results

Baseline morphometric differences between patients and controls

As presented in Table 2, cortical thickness analyses revealed that the left rACC was thinner in OCD patients in comparison with healthy controls. Patients and controls did not differ in the cortical thickness of the right rACC, the mOFC or the SC. Results from the volumetric analyses are also shown in Table 2. OCD patients and healthy controls did not differ in any of the volumetric measurements.

Morphometric correlates of exposure therapy outcome YBOCS scores

Significant negative partial correlations were observed between the cortical thickness measurements of the right mOFC and the left rACC and exposure therapy outcome assessed by the percentage of reduction in YBOCS scores. However, following the Bonferroni correction, only the association with the left rACC ($r = -0.32$, $p = 0.008$) remained statistically significant (see Fig. 2). Regarding volumetric measures, none of the ROIs assessed was significantly associated with exposure therapy results (see Table 3). Given the age range of our sample and the possible effects of menopausal status on brain measures (e.g. Goto *et al.* 2011) and fear extinction (see Zeidan *et al.* 2011), we repeated this analysis controlling for such a status in female participants, and the results remained unchanged.

To confirm the above results, a *post-hoc* hierarchical multiple regression analysis was conducted with the pre-post YBOCS percentage reduction as the dependent variable and the cortical thickness values of the six ROIs as predictor variables (stepwise method). Age, gender, lifetime MDD, total GM volume, pre-treatment depression (HAMD score) and YBOCS reduction after pharmacological trial were initially forced into the model to control for their possible influence. The results of this analysis showed that cortical thickness of the left rACC was the only significant predictor of exposure therapy outcome, explaining 8.3% of additional variance over and above the effects of the confounding covariates (full-model $R^2 = 0.27$, $F_{7,66} = 3.52$, $p = 0.003$; R^2 change after including cortical thickness of the left rACC = 0.083, $F_{1,66}$ change = 7.51, $p = 0.008$).

Table 2. Differences between OCD patients ($n=74$) and healthy controls ($n=86$) in our regions of interest^a

Region of interest	Cortical thickness, mm		<i>F</i>	<i>p</i>	Volume, mm ³		<i>F</i>	<i>p</i>
	OCD patients	Healthy controls			OCD patients	Healthy controls		
Left mOFC	4.76 (0.43)	4.85 (0.41)	2.28	0.133	2771.78 (397.70)	2903.59 (392.70)	1.21	0.274
Right mOFC	4.49 (0.39)	4.55 (0.37)	0.65	0.422	2126.78 (381.19)	2184.45 (318.18)	1.01	0.317
Left rACC	2.44 (0.19)	2.52 (0.21)	7.33	0.008 ^b	3891.64 (666.92)	4047.71 (716.92)	0.17	0.677
Right rACC	2.36 (0.17)	2.42 (0.19)	3.41	0.067	4503.19 (702.19)	4694.41 (809.89)	1.34	0.249
Left SC	2.92 (0.32)	2.96 (0.33)	0.83	0.365	736.50 (279.06)	740.91 (334.69)	0.60	0.439
Right SC	2.93 (0.34)	2.98 (0.35)	0.43	0.511	644.68 (190.84)	685.84 (240.69)	0.90	0.345

Data are given as mean (standard deviation).

OCD, Obsessive-compulsive disorder; mOFC, medial orbitofrontal cortex; rACC, rostral anterior cingulate cortex; SC, subcallosal cortex.

^aControlling for age, gender, lifetime major depressive disorder and total grey matter volume.

^bSignificant difference after Bonferroni correction.




Fig. 2. Cortical thickness of the left rostral anterior cingulate cortex (rACC) shows an inverse relationship with exposure therapy outcome [assessed as the percentage of reduction in Yale–Brown Obsessive-Compulsive Scale (YBOCS) scores, $r=-0.32$, $p=0.008$], after controlling for age, gender, lifetime major depressive disorder, total grey matter volume, pre-treatment depression score and YBOCS reduction after the pharmacological trial. Obsessive-compulsive disorder patients are labelled as responders and non-responders. CBT, Cognitive-behavioural therapy.

Treatment responders versus non-responders

Finally, we divided our patient sample into two groups according to their response to exposure therapy treatment. A total of 39 subjects were considered treatment non-responders (YBOCS reduction $<35\%$), while 35 patients did respond to exposure therapy (YBOCS reduction $\geq 35\%$). These groups did not differ in any sociodemographic or clinical variable with the exception of the YBOCS score prior to exposure therapy

initiation, which was lower in treatment responders (see Table 4). The inclusion of this variable as a further covariate in the above analyses, however, did not alter their significance. Regarding morphometric measurements, we observed that the thickness of the left rACC was significantly different across the three study groups ($F_{2,153}=4.25$, $p=0.008$), with treatment responders showing a thinner left rACC than non-responders and healthy controls. Indeed, left rACC thickness showed a significant linear increase across

Table 3. Correlational analyses of ROI measurements and exposure therapy results in OCD patients ($n=74$)^a

ROI	Cortical thickness		Volume	
	Partial correlation	p	Partial correlation	p
Left mOFC	-0.20	0.104	-0.03	0.830
Right mOFC	-0.27	0.025	-0.12	0.327
Left rACC	-0.32	0.008 ^b	-0.19	0.127
Right rACC	-0.20	0.097	-0.05	0.693
Left SC	-0.10	0.395	-0.10	0.416
Right SC	-0.17	0.161	0.04	0.726

ROI, Region of interest; OCD, obsessive-compulsive disorder; mOFC, medial orbitofrontal cortex; rACC, rostral anterior cingulate cortex; SC, subcallosal cortex; YBOCS, Yale-Brown Obsessive-Compulsive Scale.

^a Controlling for age, gender, lifetime major depressive disorder, total grey matter volume, pre-treatment depression score and YBOCS reduction after the pharmacological trial.

^b Significant correlation after Bonferroni correction.

the study groups (polynomial contrast, linear trend, $p=0.006$). The results are shown in Fig. 3.

Discussion

In the present study we aimed to investigate the relationship between the vmPFC, a brain area typically associated with fear extinction in animal and human studies (Milad & Quirk, 2012), and exposure therapy outcomes in a relatively large sample of OCD patients. Importantly, the alleged role of the vmPFC in fear extinction seems to translate into clinical practice, as the region has been associated to exposure therapy outcome in anxiety disorders (Bryant *et al.* 2008; Hoexter *et al.* 2012). Of the three sub-regions within the vmPFC assessed here, we found that the left rACC showed cortical thickness reductions in OCD patients. Also, this region was significantly associated to exposure therapy outcome. Specifically, our analyses showed that, after adjusting for unspecific confounding factors, the thickness of the left rACC explained 8% of inter-subject variability in response to exposure therapy.

Morphometric differences between OCD patients and healthy controls

In comparison with healthy controls, OCD patients showed cortical thinning in the left rACC. Conversely, none of the vmPFC sub-regions showed significant between-group differences in volume. Our results diverge from those of other studies reporting

cortical thickness reductions in OCD involving the left mOFC (Shin *et al.* 2007) and the right rACC (Venkatasubramanian *et al.* 2012). Likewise, the lack of significant between-group differences in volume measurements is at odds with previous reports of mOBF and rACC volume reductions (Pujol *et al.* 2004; Rotge *et al.* 2009). These discrepant findings may be partially attributed to methodological factors, such as the methods used for volumetric quantification and the precise clinical features of the OCD samples assessed. Thus, rACC volume reductions have mainly been detected using semi-automated or manual approaches (Rotge *et al.* 2009), but not with automated approaches (Radua & Mataix-Cols, 2009; Rotge *et al.* 2010), while mOBF volume reductions have particularly been observed in subsamples of OCD patients with co-morbid major depressive disorder (Cardoner *et al.* 2007). Indeed, the thorough control of possible confounding factors (i.e. lifetime MDD) performed here must certainly have contributed to circumscribe our findings to those regions more specifically related to OCD. All in all, comparisons between different methodological approaches and OCD samples differing in particular clinical features would need to be conducted in order to fully characterize the nature of such alterations. Be that as it may, the existence of structural abnormalities in brain regions relevant to the consolidation and retention of fear extinction is in agreement with the idea that fear extinction deficits may partially account for the constellation of symptoms observed in OCD subjects (Milad & Rauch, 2012).

Prediction of exposure therapy outcome and the vmPFC

Cortical thickness of the left rACC was negatively associated with the response to exposure therapy. Although it might be argued that a correlation value of 0.32 is not particularly 'strong', it does indeed imply that 8% of the variability in exposure therapy response may be explained by morphometric factors. In addition, our correlational findings were further supported by the direct comparison between treatment responders and non-responders, showing a decreased cortical thickness in the left rACC of responder subjects. Although such data are broadly in agreement with the findings of Bryant *et al.* (2008), in that they reported an association between regional volumes within the rACC and treatment response to exposure-based CBT in PTSD patients, there are significant differences between both studies. Apart from using a different patient population (PTSD *versus* OCD) and a different methodological approach (spatially constrained voxel-wise volumetric-only assessment *versus* the ROI approach used here to assess both cortical

Table 4. Sociodemographic and clinical variables in exposure therapy responders and non-responders

	Responders (<i>n</i> =35)	Non-responders (<i>n</i> =39)	Statistic ^a	<i>p</i>
Mean age, years (s.d., range)	34.11 (9.77, 19–57)	34.08 (8.83, 21–54)	−0.017	0.986
Mean age at OCD onset, years (s.d.)	23.20 (7.55)	20.13 (7.29)	−1.779	0.079
Mean duration of education, years (s.d.)	12.57 (3.00)	12.28 (3.14)	−0.404	0.687
Gender, male, <i>n</i> (%)	15 (42.9)	23 (58.9)	1.988	0.172
Co-morbidity				
Affective disorders, <i>n</i> (%)	4 (11.4)	9 (23.1)	1.728	0.231
Major depressive disorder, <i>n</i>	2	3		
Dysthymia, <i>n</i>	2	2		
Depressive disorder not otherwise specified, <i>n</i>	0	4		
Anxiety disorders, <i>n</i> (%)	3 (8.6)	6 (15.4)	0.802	0.486
Social phobia, <i>n</i>	1	3		
Panic disorder, <i>n</i>	1	2		
Generalized anxiety disorder, <i>n</i>	1	1		
Tic disorders, <i>n</i> (%)	3 (8.6)	4 (10.3)	0.061	1.000
Family history of OCD, <i>n</i> (%)	5 (14.3)	10 (25.6)	1.472	0.260
Mean HAMD baseline (s.d.)	13.43 (4.26)	12.44 (4.69)	0.949	0.346
Mean YBOCS-obsessions baseline (s.d.)	10.26 (2.58)	12.13 (2.47)	3.183	0.002
Mean YBOCS-compulsions baseline (s.d.)	10.17 (2.44)	11.72 (2.54)	2.660	0.010
Mean YBOCS-total baseline (s.d.)	20.43 (4.89)	23.85 (4.85)	3.014	0.004
Pharmacological treatment, <i>n</i> (%)			0.882	0.830
Fluoxetine 60–80 mg/day	19 (54.3)	18 (46.2)		
Fluvoxamine 200–300 mg/day	7 (20.0)	9 (23.1)		
Escitalopram 20–40 mg/day	5 (14.3)	5 (12.8)		
Clomipramine 225–300 mg/day	4 (11.4)	7 (18.0)		

s.d., Standard deviation; OCD, obsessive-compulsive disorder; HAMD, Hamilton Depression Rating Scale; YBOCS, Yale-Brown Obsessive-Compulsive Scale.

^a For quantitative variables, *t* test; for qualitative variables, χ^2 .




Fig. 3. Cortical thickness of the left rostral anterior cingulate cortex (rACC, adjusted for confounding covariates) in exposure therapy responders and non-responders and healthy controls. Values are means, with standard deviations represented by vertical lines. The significant linear increase observed across groups is represented by a solid line.

thickness and volume), Bryant's study showed a volumetric decrease in non-responders when compared with responders, whereas ours demonstrates the opposite pattern of results relating to cortical thickness.

Indeed, although negative relationships between morphometric measurements and treatment response have been detected in other disorders (e.g. Arango *et al.* 2003), larger volumes or thicker cortices within the

vmPFC (regardless of its precise location) have been typically associated with better fear extinction in both non-clinical (Milad *et al.* 2005; Hartley *et al.* 2011) and clinical populations (Hoexter *et al.* 2012).

Although the precise factors (methodological or others) leading to such contradictory results between studies remain elusive, it is noteworthy that, in a recent functional MRI study, a favourable response to CBT was associated with decreased activity in the rACC (Siegle *et al.* 2012). Such a finding was interpreted in terms of the possibility that CBT provides or restores the necessary resources for an effective cortical inhibition of limbic activity, favouring top-down control strategies (Linden, 2008). By contrast, drug therapy is supposed to directly down-regulate limbic activity, and indeed increased pre-treatment activity in the rACC predicts good response to antidepressant treatment in depressive patients (Chen *et al.* 2007). Further research would be needed to confirm whether such notions might also apply to morphometric measurements. Nevertheless, one possible explanation for our findings is that patients with smaller cortical thickness in the rACC show a greater fear extinction dysfunction and are therefore the best candidates for improvement after a therapy that is specifically tailored to enhance fear extinction capabilities. Alternatively, it may be also noted that the role of cortico-limbic interactions may differ depending on the brain hemisphere. Thus, while in the right hemisphere the interaction between the rACC and the amygdala seems to mediate behavioural adaptation to aversive events (for instance, in fear-conditioning paradigms), left rACC and amygdala interactions seem to mediate the effects of negative affect (Polli *et al.* 2009). In this sense, a left-lateralized reduction of rACC thickness may favour behavioural adaptations without interfering modulations from negative affect.

Beyond the above-mentioned correlation between rACC thickness and CBT response, we also observed a tendency to significance in terms of the correlation between the cortical thickness of the right mOFC and exposure therapy outcome. Again, however, it should be pointed out that our results differ from those reported by Milad *et al.* (2005), in which a thicker mOFC predicted a better retention of extinction learning. Nevertheless, such findings suggest that the mOFC may also play a relevant role in exposure therapy outcome, which should be researched further. Furthermore, contrary to what was recently reported by Hoexter *et al.* (2012), we did not observe any relation between the SC and treatment response. Nevertheless, contrary to what has been consistently reported for mood disorders (Fu *et al.* 2013), the SC has not been consistently related to OCD.

Strengths and limitations

The strengths of the present study include a clear hypothesis-driven approach based on solid translational research, a relatively large sample of patients and controls and the use of two different morphometric measurements. Its main limitation is that all the patients involved were undergoing pharmacological treatment and, therefore, morphometric assessments were subject to this potentially confounding factor. Although there is some concern as to the effects that psychotropic substances may have on brain anatomy, little evidence exists to suggest that OCD medication may induce morphometric brain alterations, such as neuronal loss or gliosis (Konradi & Heckers, 2001). Furthermore, a meta-analysis of VBM studies performed with OCD samples concluded that medication has little effect on GM volume measurements (Radua & Mataix-Cols, 2009). Likewise, in another study assessing whole-brain cortical thickness, the measures of medication exposure were not correlated with the thickness of any cortical region showing a significant thinning in the sample of OCD patients (Shin *et al.* 2007). Although the concurrent use of medication may limit the internal validity of our study, it nonetheless increases its clinical relevance, as, in everyday clinical practice, many OCD patients receive combined (i.e. medication plus exposure therapy) treatments (e.g. Boschen & Drummond, 2012).

Furthermore, from a conceptual perspective, it might be argued that the evidence supporting the translation from fear extinction in the laboratory to exposure therapy in clinical practice is limited. Nevertheless, in at least one clinical study (with patients suffering from social anxiety disorder), a significant relationship was found between extinction retention and exposure therapy outcome (Berry *et al.* 2009). Likewise, certain molecules facilitating fear extinction (e.g. D-cycloserine) have been shown to improve exposure therapy outcome in clinical samples (see Norberg *et al.* 2008). Finally, although fear extinction (and retention) deficits may be characteristic of most anxiety disorders, such deficits have, to date, mainly been detected in PTSD patients (Milad *et al.* 2008, 2009) and, so far, only one study has shown them to characterize OCD (Milad *et al.* 2013). Nevertheless, fear extinction mechanisms have not been thoroughly investigated in OCD (Milad & Rauch, 2012).

Implications

First, from an academic point of view, the present research highlights the idea that the study of fear extinction and its brain correlates may provide new insight into the pathophysiology of OCD

(Milad & Rauch, 2012). Second, from a methodological perspective, our findings indicate that the combined assessment of both volumetric and cortical thickness measurements may help in detecting the most relevant anatomical features associated with outcome variables. The results reported here suggest that cortical thickness measurements are more directly related to treatment outcome measurements. Indeed, integrating such morphometric measurements with other imaging (e.g. functional) and non-imaging (e.g. neuropsychological, genetic, or clinical) variables may increase our ability to predict treatment response.

Finally, the present study is also clinically significant insofar as it suggests that the assessment of the brain correlates of fear extinction may eventually lead to a better prediction of treatment response and/or the identification of new treatment targets. This latter aspect is especially relevant since current treatment options for severe OCD include neuromodulation strategies (Greenberg *et al.* 2010), and a better understanding of the brain areas involved in fear extinction may well guide such interventions. To this effect, for example, a recent study showed that repeated transcranial magnetic stimulation (rTMS) in combination with extinction training may enhance fear extinction in rats (Baek *et al.* 2012). In humans, a preliminary study in PTSD patients showed that adding rTMS to exposure therapy may also provide certain clinical benefits (Osuch *et al.* 2009). Studies like the one presented here may contribute to the optimization of the different treatment strategies available for OCD and ultimately serve to improve patient management.

Acknowledgements

This study was supported in part by the Carlos III Health Institute (PI09/01331 PI10/01753, PI10/01003, CP10/00604, CIBER-CB06/03/0034) and by the Agencia de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2009SGR1554). M.S. is funded by the Bellvitge Biomedical Research Institute (IDIBELL). C.L-S. is supported by the Spanish Ministry of Education, Culture and Sport (FPU12/01636). E.R. is supported by a 'Rio Hortega' contract from the Carlos III Health Institute (I.D. CM11/00077). C.S-M. is funded by a 'Miguel Servet' contract from the Carlos III Health Institute (CP10/00604). We also thank Gerald Fannon for revising the manuscript.

Declaration of Interest

None.

References

- Abramowitz JS (2006). The psychological treatment of obsessive-compulsive disorder. *Canadian Journal of Psychiatry* **51**, 407–416.
- APA (1994). *Diagnostic and Statistical Manual of Mental Disorders*, 4th edn. American Psychiatric Association: Washington, DC.
- Arango C, Breier A, McMahon R, Carpenter Jr. WT, Buchanan RW (2003). The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. *American Journal of Psychiatry* **160**, 1421–1427.
- Baek K, Chae JH, Jeong J (2012). The effect of repetitive transcranial magnetic stimulation on fear extinction in rats. *Neuroscience* **200**, 159–165.
- Berry AC, Rosenfield D, Smits JA (2009). Extinction retention predicts improvement in social anxiety symptoms following exposure therapy. *Depression Anxiety* **26**, 22–27.
- Boschen MJ, Drummond LM (2012). Community treatment of severe, refractory obsessive-compulsive disorder. *Behaviour Research and Therapy* **50**, 203–209.
- Bouton ME (2004). Context and behavioral processes in extinction. *Learning and Memory* **11**, 485–494.
- Bryant RA, Felmingham K, Whitford TJ, Kemp A, Hughes G, Peduto A, Williams LM (2008). Rostral anterior cingulate volume predicts treatment response to cognitive-behavioural therapy for posttraumatic stress disorder. *Journal of Psychiatry and Neuroscience* **33**, 142–146.
- Cardoner N, Soriano-Mas C, Pujol J, Alonso P, Harrison BJ, Deus J, Hernandez-Ribas R, Menchon JM, Vallejo J (2007). Brain structural correlates of depressive comorbidity in obsessive-compulsive disorder. *Neuroimage* **38**, 413–421.
- Chen CH, Ridler K, Suckling J, Williams S, Fu CH, Merlo-Pich E, Bullmore E (2007). Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. *Biological Psychiatry* **62**, 407–414.
- Destrieux C, Fischl B, Dale A, Halgren E (2010). Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. *Neuroimage* **53**, 1–15.
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). *Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV)*. American Psychiatric Press, Inc.: Washington, DC.
- First MB, Spitzer RL, Gibbon M, Williams JBW (2002). *Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP)*. Biometrics Research, New York State Psychiatric Institute: New York.
- Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM (2002). Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron* **33**, 341–355.
- Fischl B, Salat DH, van der Kouwe AJ, Makris N, Segonne F, Quinn BT, Dale AM (2004). Sequence-independent segmentation of magnetic resonance images. *Neuroimage* **23** (Suppl. 1), S69–S84.

- Fu CH, Steiner H, Costafreda SG (2013). Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. *Neurobiology of Disease* **52**, 75–83.
- Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989). The Yale–Brown Obsessive Compulsive Scale: I. Development, use, and reliability. *Archives of General Psychiatry* **46**, 1006–1011.
- Goto M, Abe O, Miyati T, Inano S, Hayashi N, Aoki S, Mori H, Kabasawa H, Ino K, Yano K, Iida K, Mima K, Ohtomo K (2011). 3 Tesla MRI detects accelerated hippocampal volume reduction in postmenopausal women. *Journal of Magnetic Resonance Imaging* **33**, 48–53.
- Graham BM, Milad MR (2011). The study of fear extinction: implications for anxiety disorders. *American Journal of Psychiatry* **168**, 1255–1265.
- Greenberg BD, Rauch SL, Haber SN (2010). Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. *Neuropsychopharmacology* **35**, 317–336.
- Hamilton M (1960). A rating scale for depression. *Journal of Neurology, Neurosurgery and Psychiatry* **23**, 56–62.
- Hartley CA, Fischl B, Phelps EA (2011). Brain structure correlates of individual differences in the acquisition and inhibition of conditioned fear. *Cerebral Cortex* **21**, 1954–1962.
- Hoexter MQ, Dougherty DD, Shavitt RG, D'Alcante CC, Duran FL, Lopes AC, Diniz JB, Batistuzzo MC, Evans KC, Bressan RA, Busatto GF, Miguel EC (2012). Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder. *European Neuropsychopharmacology*. Published online 26 July 2012. doi:10.1016/j.euroneuro.2012.06.014.
- Hofmann SG (2007). Enhancing exposure-based therapy from a translational research perspective. *Behaviour Research and Therapy* **45**, 1987–2001.
- Hutton C, Draganski B, Ashburner J, Weiskopf N (2009). A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. *Neuroimage* **48**, 371–380.
- Kalisch R, Korenfeld E, Stephan KE, Weiskopf N, Seymour B, Dolan RJ (2006). Context-dependent human extinction memory is mediated by a ventromedial prefrontal and hippocampal network. *Journal of Neuroscience* **26**, 9503–9511.
- Konradi C, Heckers S (2001). Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. *Biological Psychiatry* **50**, 729–742.
- Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. *American Journal of Psychiatry* **164**, 5–53.
- Kozak M, Foa EB (1997). *Mastery of your Obsessive-Compulsive Disorder*. Psychological Corp.: San Antonio, TX.
- Labate A, Cerasa A, Mula M, Mumoli L, Gioia MC, Aguglia U, Quattrone A, Gambardella A (2012). Neuroanatomic correlates of psychogenic nonepileptic seizures: a cortical thickness and VBM study. *Epilepsia* **53**, 377–385.
- Linden DE (2008). Brain imaging and psychotherapy: methodological considerations and practical implications. *European Archives of Psychiatry and Clinical Neurosciences* **258** (Suppl. 5), 71–75.
- Milad MR, Furtak SC, Greenberg JL, Keshaviah A, Im JJ, Falkenstein MJ, Jenike M, Rauch SL, Wilhelm S (2013). Deficits in conditioned fear extinction in obsessive-compulsive disorder correlate to neurobiological changes in the fear circuit. *Journal of the American Medical Association*. Published online 17 April 2013. doi:10.1001/jama.2010.920.
- Milad MR, Orr SP, Lasko NB, Chang Y, Rauch SL, Pitman RK (2008). Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. *Journal of Psychiatric Research* **42**, 515–520.
- Milad MR, Pitman RK, Ellis CB, Gold AL, Shin LM, Lasko NB, Zeidan MA, Handwerker K, Orr SP, Rauch SL (2009). Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. *Biological Psychiatry* **66**, 1075–1082.
- Milad MR, Quinn BT, Pitman RK, Orr SP, Fischl B, Rauch SL (2005). Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory. *Proceedings of the National Academy of Sciences USA* **102**, 10706–10711.
- Milad MR, Quirk GJ (2012). Fear extinction as a model for translational neuroscience: ten years of progress. *Annual Review of Psychology* **63**, 129–151.
- Milad MR, Rauch SL (2012). Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. *Trends in Cognitive Sciences* **16**, 43–51.
- Milad MR, Wright CI, Orr SP, Pitman RK, Quirk GJ, Rauch SL (2007). Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. *Biological Psychiatry* **62**, 446–454.
- Norberg MM, Krystal JH, Tolin DF (2008). A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. *Biological Psychiatry* **63**, 1118–1126.
- Osuch EA, Benson BE, Luckenbaugh DA, Geraci M, Post RM, McCann U (2009). Repetitive TMS combined with exposure therapy for PTSD: a preliminary study. *Journal of Anxiety Disorders* **23**, 54–59.
- Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J; International Treatment Refractory OCD Consortium (2002). Treatment non-response in OCD: methodological issues and operational definitions. *International Journal of Neuropsychopharmacology* **5**, 181–191.
- Phelps EA, Delgado MR, Nearing KI, LeDoux JE (2004). Extinction learning in humans: role of the amygdala and vmPFC. *Neuron* **43**, 897–905.
- Polli FE, Wright CI, Milad MR, Dickerson BC, Vangel M, Barton JJ, Rauch SL, Manoach DS (2009). Hemispheric

- differences in amygdala contributions to response monitoring. *Neuroreport* **20**, 398–402.
- Pujol J, Soriano-Mas C, Alonso P, Cardoner N, Menchon JM, Deus J, Vallejo J** (2004). Mapping structural brain alterations in obsessive-compulsive disorder. *Archives of General Psychiatry* **61**, 720–730.
- Quirk GJ, Mueller D** (2008). Neural mechanisms of extinction learning and retrieval. *Neuropsychopharmacology* **33**, 56–72.
- Radua J, Mataix-Cols D** (2009). Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. *British Journal of Psychiatry* **195**, 393–402.
- Rauch SL, Shin LM, Phelps EA** (2006). Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research – past, present, and future. *Biological Psychiatry* **60**, 376–382.
- Rotge JY, Guehl D, Dilharreguy B, Tignol J, Bioulac B, Allard M, Burbaud P, Aouizerate B** (2009). Meta-analysis of brain volume changes in obsessive-compulsive disorder. *Biological Psychiatry* **65**, 75–83.
- Rotge JY, Langbour N, Guehl D, Bioulac B, Jaafari N, Allard M, Aouizerate B, Burbaud P** (2010). Gray matter alterations in obsessive-compulsive disorder: an anatomic likelihood estimation meta-analysis. *Neuropsychopharmacology* **35**, 686–691.
- Shin YW, Yoo SY, Lee JK, Ha TH, Lee KJ, Lee JM, Kim IY, Kim SI, Kwon JS** (2007). Cortical thinning in obsessive compulsive disorder. *Human Brain Mapping* **28**, 1128–1135.
- Siegle GJ, Thompson WK, Collier A, Berman SR, Feldmiller J, Thase ME, Friedman ES** (2012). Toward clinically useful neuroimaging in depression treatment: prognostic utility of subgenual cingulate activity for determining depression outcome in cognitive therapy across studies, scanners, and patient characteristics. *Archives of General Psychiatry* **69**, 913–924.
- Sotres-Bayon F, Cain CK, LeDoux JE** (2006). Brain mechanisms of fear extinction: historical perspectives on the contribution of prefrontal cortex. *Biological Psychiatry* **60**, 329–336.
- Venkatasubramanian G, Zutshi A, Jindal S, Srikanth SG, Kovoor JM, Kumar JK, Janardhan Reddy YC** (2012). Comprehensive evaluation of cortical structure abnormalities in drug-naïve, adult patients with obsessive-compulsive disorder: a surface-based morphometry study. *Journal of Psychiatric Research* **46**, 1161–1168.
- Zeidan MA, Igwe SA, Linnman C, Vitalo A, Levine JB, Klibanski A, Goldstein JM, Milad MR** (2011). Estradiol modulates medial prefrontal cortex and amygdala activity during fear extinction in women and female rats. *Biological Psychiatry* **70**, 920–927.